



Medicare Hospice Benefit II: Places of Care and Funding

Robin Turner MD, Kimberly Mallin MD, Drew A Rosielle MD


Medicare Hospice Benefit Part I described eligibility for the Medicare Hospice Benefit (MHB) and the services it covers. This Fast Fact will review where hospice services are provided and the reimbursement system. Medicare Hospice Benefit Part III reviews special interventions under the MHB and the last in the series further discusses levels of care.

Places of Care

- Home** The majority (~95%) of hospice care takes place in the home. Hospice team members visit the patient and family on an intermittent basis determined by the Plan of Care, which changes based on the patient's needs. Medicare rules do not require a primary caregiver in the home, but as death nears, it becomes increasingly difficult to provide care for a patient who does not have someone (family, friends, hired caregivers) who can be present 24 hours a day in the home.
- Long-term care facility** 25% of patients in the US die in nursing homes. Medicare recognizes that this can be the resident's 'home' and that the patient's 'family' frequently includes the nursing home staff. Hospice care under the MHB can be provided to residents in addition to usual care provided by the facility. Individual hospice programs must establish a contract with the facility to provide hospice care. The MHB does not pay for nursing home room and board charges.
- Hospice inpatient unit** Dedicated units, either free-standing or within other facilities (such as nursing homes or hospitals) are available in some regions. Patient eligibility (e.g., whether a patient requires general inpatient care), permitted length-of-stay, and fees for room and board vary between facilities.
- Hospital** When pain or other symptoms related to the terminal illness cannot be managed at home, the patient may be admitted to a hospital for more intensive management, still under the MHB. The hospital must have a contract with the hospice program to provide this service.

Payment Medicare pays for covered services using a per diem capitated arrangement in one of four categories. There are variances in reimbursement based on region and whether the hospice agency is compliant with providing quality data. Therefore, the rates below reflect approximate information reflecting the 2021 Medicare and Medicaid reimbursements intended to convey general orders of magnitude of payment. Payment is made from Medicare to the hospice agency, which then pays the hospital or nursing home (for respite or acute care), depending on the specifics of the contractual arrangement between the hospice agency and the facility.

- Routine Home Care** care at home or a nursing home. Reimbursement varies depending on the patient's length of enrollment in hospice (days 1-60 approximately \$200/day; Days 61+ approximately \$155/day).
- Respite Care** care in an inpatient setting (nursing home, hospice facility, or hospital) for up to 5 days to give caregivers a rest (\$455/day).



- **General Inpatient Care (GIP)** acute inpatient care (at a hospital or hospice facility) for conditions related to the terminal illness such as pain and symptom control, caregiver breakdown, or impending death that requires inpatient-level interventions (\$1035/day).
- **Continuous Home Care** provides acute care at home with around-the-clock nursing for a crisis that might otherwise lead to inpatient care (\$1420/day)

Clinician Services Direct patient care services by clinicians, for care related to the terminal illness, are reimbursed by Medicare, and are not included in the per diem. If the attending physician is not associated with the hospice program via employment or similar contract, the physician bills Medicare Part B in the usual fashion. The bill must indicate that the physician is not associated with the hospice program, or the claim may be denied. If the attending is associated with the hospice program (e.g., as a hospice medical director) the physician submits the bill to the hospice program, which in turn submits the claim to Medicare under Part A. The physician is then reimbursed based on a contract with the hospice program. Patients can see consulting physicians under the MHB if the hospice agency contracts with the consultant to do so. The hospice agency submits the claim under Medicare Part A and reimburses the consultant per their contract.

REFERENCES

- 1 **von Gunten CF, et al.** Coding and reimbursement mechanisms for physician services in hospice and palliative care. *J Pall Med.* 2000; 3:157-164.
- 2 **Gazelle G.** Understanding hospice – an underutilized option for life’s final chapter. *NEJM.* 2007; 357:321-324.
- 3 **Hospice Center.** Centers for Medicare and Medicaid Services. Available at: <https://www.cms.gov/Center/Provider-Type/Hospice-Center> accessed December 20, 2021
- 4 **National Hospice and Palliative Care Organization.** “The Medicare Hospice Benefit.” January 2015. Available at: <https://www.nhpco.org/wp-content/uploads/NHPCO-Facts-Figures-2020-edition.pdf> accessed December 20, 2021
- 5 **CGS Medicare.** “Hospice Payment Rates.” Available at: <https://www.cms.gov/files/document/mm11876.pdf> accessed December 20, 2021

Version History Originally edited by David E Weissman MD. 2nd Edition was edited by Drew A Rosielle MD and published November 2007. It was re-copy-edited April 2009 and February 2016. In January 2022 in underwent more substantive content changes by Kimberly Mallin MD.

Copyright All Fast Facts and Concepts are published under permission from PCNW and Creative Commons Attribution - NonCommercial 4.0 International Copyright (<http://creativecommons.org/licenses/by-nc/4.0/>).

Disclaimer Fast Facts and Concepts provide educational information for health care professionals. This information is not medical advice. Fast Facts are not continually updated, and new safety information may emerge after a Fast Fact is published. Health care providers should always exercise their own independent clinical judgment and consult other relevant and up-to-date experts and resources. Some Fast Facts cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.